ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PVLA vs MRVI // EV/EBITDA & P/E VALUATION

Palvella Therapeutics Inc. (NASDAQ) VS. Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: PVLA 3 — MRVI 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PVLA VS. MRVI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PVLA MRVI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 18.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.90% -35.00% +7.10 PVLA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -1.14% -3.22% +2.08 PVLA /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -28.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.04 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 MRVI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.5 53.6 +5.99 PVLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.18B $2.20B -$12.8M MRVI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PVLA REV MRVI REV PVLA GROSS % MRVI GROSS % PVLA FCF MRVI FCF
FY 2025 $0 $185.7M — 18.3% -$25.0M -$70.7M
FY 2024 $0 $259.2M — 41.8% -$10.8M -$22.2M
FY 2023 $42.8M $288.9M — — -$13.7M $126.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PVLA // BETA —
MRVI // BETA —